Merck & Co (NY:MRK)

Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b study findings.

Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?

February 26, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session

February 26, 2024

Via Benzinga

3 Top Pharma Stocks for Investors Betting on a Biotech Boom

February 26, 2024

Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Behind the Scenes of Merck & Co's Latest Options Trends

February 26, 2024

Via Benzinga

What the Options Market Tells Us About Merck & Co

February 15, 2024

Via Benzinga

Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals

February 14, 2024

Via Benzinga

Merck & Company Inc. (NYSE: MRK) Records 52-Week High Monday Morning

February 05, 2024

Via Investor Brand Network

February 23, 2024

Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.

3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List

February 22, 2024

Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...

Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment

February 22, 2024

Via Benzinga

Topics Intellectual Property

Exposures COVID-19 Intellectual Property

2 Monster Stocks to Buy Without Any Hesitation

February 22, 2024

Investors can sleep easy at night with these stocks in their portfolios.

Via The Motley Fool

MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential

February 22, 2024

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Via Talk Markets

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

February 20, 2024

Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks

February 16, 2024

Via Benzinga

Topics Economy

Exposures Economy

3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report

February 15, 2024

Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth.

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END

Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

February 15, 2024

Via FinancialNewsMedia

Drivers And Stock Pickers

February 13, 2024

As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient.

Via Talk Markets

A Look At Pharma ETFs After Q4 Earnings

February 12, 2024

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.

Via Talk Markets

Topics ETFs

Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

February 15, 2024

From FN Media Group LLC

Via GlobeNewswire

This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate

February 12, 2024

United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ:

Via Benzinga

Topics Intellectual Property

Exposures Intellectual Property

2 Value Stocks With Monster Yields

February 12, 2024

These two low-priced large-cap stocks sport ginormous yields.

Via The Motley Fool

Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

February 09, 2024

Via Benzinga

Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

February 08, 2024

Investors are still excited about obesity treatments and weight-management drugs.

Via The Motley Fool

Are these frigid Dow stocks in for a longer winter?

February 08, 2024

These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages.

Via MarketBeat

Topics Economy Stocks

Exposures Economy US Equities

2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front

February 07, 2024

On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...

Via Benzinga

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

February 06, 2024

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

Earning season is well underway, and the separation between the winners and losers continues to grow. Of the companies that have beat

3 companies that more than doubled analyst EPS estimates

February 06, 2024

Via MarketBeat

Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden

February 05, 2024

"Merck Animal Health expands aqua portfolio with the $1.3 billion acquisition of Elanco's aqua business. Expected completion by mid-2024."

Via Benzinga

Merck Animal Health to Acquire Elanco’s Aqua Business

February 05, 2024